Abstract: The present disclosure relates to an inhibitor of Dynamin 2 for use in the treatment of centronuclear myopathies. The present disclosure relates to pharmaceutical compositions containing Dynamin 2 inhibitor and to their use for the treatment of centronuclear myopathies. It also deals with a method for identifying or screening molecules useful in the treatment of a centronuclear myopathy.

Abstract: The present invention concerns a polyelectrolyte coating comprising at least one polycationic layer consisting of at least one polycation consisting of n repetitive units having the formula (1) and at least one polyanionic layer consisting of hyaluronic acid. The polyelectrolyte coating has a biocidal activity and the invention thus further refers to the use of said polyelectrolyte coating for producing a device, in particular a bacteriostatic medical device, more particularly an implantable device, comprising said polyelectrolyte coating, and a method for preparing said device and a kit.

Abstract: The present invention relates to GFLV virus-like particles and the uses thereof in various fields, such as the pharmaceutical, agro, or veterinary areas.

Abstract: Disclosed is a device including at least one circulating zone and at least one fluid including at least one more-paramagnetic liquid and at least one less-paramagnetic liquid forming a liquid-liquid interphase, the device including at least one element generating, in the circulating zone, a magnetic field, wherein the less-paramagnetic liquid is surrounded by the more-paramagnetic liquid in the circulating zone or wherein the more-paramagnetic liquid is surrounded by the less-paramagnetic liquid in the circulating zone. Also disclosed is a method including circulating at least one less-paramagnetic liquid inside one or more circulating zones of a device including at least one circulating zone and at least one more-paramagnetic liquid in the circulating zone.

Abstract: RNA aptamers are disclosed with distinct fluorescent properties, fluorophore binding affinities, and salt dependence. Also disclosed are corresponding fluorophores, with selected fluorophores evidencing high cellular permeability. The aptamer's high fluorophore affinities, the high brightness of the bound complexes, and their thermal and salt stability, provide distinct aspects of the disclosed aptamers.

Abstract: Enantiopure terphenyl presenting two ortho-located chiral axes having the following structural formula (I): their process of synthesis and their use as mono or bidentate ligands for asymmetric organometallic reactions, as organocatalysts, as chiral base and as generator, with metal, of isolable chiral metallic complexes for applications in asymmetric catalysis and others.

Abstract: Disclosed is a compound of formula (II), as well as to a process for preparing the compounds of formula (II) by a chemoselective Sonogashira reaction. It also relates to a pharmaceutical composition including at least one compound of formula (II) and at least one pharmaceutically acceptable support. Finally, it relates to the use of such a compound as a medicine, preferably in the treatment of a nervous and/or respiratory failure due to intoxication with at least one organophosphorous nerve agent; in the treatment of neurological diseases such as Alzheimer's disease; and/or in the treatment of cancer; and/or for use as antiviral drug.

Abstract: The present invention relates to humanized anti-claudin-1 antibodies and uses thereof. Hepatitis C virus infection is a leading cause of chronic liver disease and a major indication for liver transplantation. For clinical development, the inventors have humanized a rat anti-CLDN1 antibody produced by genetic immunization that prevent HCV infection and also cure chronically infected human liver chimeric mice. The lead humanized anti-CLDN1 antibody (H3L3) pan-genotypically inhibited HCV pseudoparticle infection of primary human hepatocytes (PHH) without detectable escape. H3L3 efficiently inhibited infection by diverse HCV genotype 3 strains and exhibited marked synergy with direct-acting antivirals (DAAs).

Abstract: Disclosed are a method for preparing a hydroalcoholic extract obtained from a biomass of the shoots of a plant from the family of Plumbaginaceae, a butanol extract of Armenia maritima, a method for the preparation thereof, the use thereof, and compositions containing same.

Abstract: The present invention relates to peptides for the treatment or prevention of diabetes mellitus and associated disorders.

Abstract: The invention relates to a method for manufacturing a semiconductor component comprising a thin layer of crystalline silicon on a substrate, comprising the steps of: providing a silicon-rich aluminum substrate (S0), depositing a thin layer of amorphous silicon on the substrate (S1), and applying thermal annealing (S2) to the thin layer of amorphous silicon to obtain a thin layer of crystalline silicon on the substrate.

Abstract: A method for modifying a cellular polymer foam with apparent porosity, which includes providing a cellular polymer foam with apparent porosity, placing the cellular polymer foam in contact with at least one compound in order to obtain a cellular polymer foam including on the surface thereof an intermediate phase formed from the compound having at least one catechol unit. The foam may be used as a catalyst substrate.

Abstract: The invention relates to a method of producing CD34+CD4dim megakaryocyte (MK) progenitor cells, and substantially pure cell population of megakaryocyte precursor cells obtained by said method. The invention also relates to a method of producing proplatelet-bearing MKs and/or platelets using the CD34+CD4dim cells.

Abstract: The present invention relates to novel fusion polypeptides and the uses thereof. The invention particularly relates to conjugated coat proteins derived from nepoviruses, virus-like particles made with such proteins, and the uses thereof. The particles of the invention can expose and/or encage molecules of interest and have utility in various fields such as the pharmaceutical, agro, or veterinary areas.

Abstract: A method for determining a configuration setting of a source of ionizing radiation reducing a radiation dose absorbed by a patient and a practitioner in a medical operating room during a procedure. Prior to the procedure a database of maps of simulated propagation and scattering of ionizing radiation in a model of the medical operating room is obtained for different configuration settings. During the procedure, a position of the practitioner is determined. After determining a set of configuration settings of the source enabling the production of an image of a target anatomical structure a radiation dose absorbed by the patient and the practitioner is determined using the maps from the database. A recommended configuration setting for which a combined radiation dose is reduced is then outputted.

Abstract: The present invention relates to a method for capturing a molecular target present in the aqueous phase of a water-in-oil emulsion, said method being based on the use of a binding system comprising (a) a surfactant bearing a functional moiety on its hydrophilic head group and (b) a chemoprobe that acts as a molecular staple between the functionalized surfactant and the molecular target and comprises at least two distinct domains namely (i) at least one capture moiety which is able to specifically bind the molecular target and (ii) at least one binding domain which is able to interact with the functional group of the surfactant through covalent or non-covalent interactions, directly or through a binding intermediary.

Abstract: A polyester polyol of formula produced by a first polycondensation (a) of a sugar alcohol Z in C3 to C8 and two diacids Y and Y? which are the same or different in C4 to C36, and a second polycondensation (b) of the product produced in (a) with two diols X and X? which are the same or different in C2 to C12, the polymer including such a polyester polyol. Also, a method for producing the polyester polyols and the use thereof in foams, adhesives, coatings or elastomers of polyurethane or polyisocyanurate.

Abstract: An optical guide for a near-eye display device includes a first guide element having a light input zone and a second guide element having an output zone. The first guide element is superimposed on the second guide element. The optical guide also includes an optical coupling system between the first guide element and the second guide element, and the first and second guide elements have, on the first part of their length, a mutual spacing so as to delimit a thin layer of air between said guide elements extending between a first longitudinal end of the guide elements and the optical coupling system. The optical coupling system, located at a second longitudinal end of the first and second guide elements, includes a single-piece portion of the guide elements, associated with an optical reflection member to propagate the beams of light from the input zone toward the output zone.

Abstract: A protective helmet includes an inner cap, an outer cap and a decoupling layer capable of allowing the outer cap to rotate relative to the inner cap about any axis of rotation in the event of an impact. At least one spherical surface is completely contained in the decoupling layer. The helmet includes a fastening strap attached at two opposing points of the inner cap without any mechanical connection with the outer cap. The strap is intended to fasten the helmet to the head of the wearer. The helmet includes a fastening frame attached to the inner cap, and the strap is attached to the inner cap by the fastening frame.

Abstract: The present invention provides a simple and robust human liver cell-based system in which persistent hepatitis C infection, persistent hepatitis B infection or ethanol exposure induces a clinical Prognostic Liver Signature (PLS) high-risk gene signature. The cellular model system for hepatocellular carcinoma (HCC)/cirrhosis development and progression may be used in the screening of compounds useful in the treatment and/or prevention of cirrhosis and/or HCC as well as in the identification biomarkers for the prediction of liver disease (especially cirrhosis) progression and HCC. The present invention also relates to specific compounds that have been identified, using such screening methods, as useful in the treatment and/or the prevention of HCC/cirrhosis.